Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data MEDICURE INC files with the SEC in its annual reports.
In CAD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Revenue
22.1
29.3
27.1
29.1
20.2
11.6
21.7
23.1
21.7
21.9
Cost of revenue
2.26
3.72
3.47
4.15
7.27
6.48
9.03
6.99
7.71
8.82
Gross profit
19.8
25.6
23.7
25
12.9
5.13
12.7
16.1
14
13.1
Research and development
4.87
3.63
5.15
6.68
4.35
3.3
1.8
2.75
2.41
3.08
Selling, general and administrative
10.2
15.4
14.9
19.5
Selling and marketing
11.5
15.6
13.4
5.36
10.3
7.94
8.31
7.98
General and administrative
0.95
1.53
1.73
1.51
0.82
0.4
1.4
1.38
0.55
0.96
Operating income
4.72
6.54
3.65
-1.23
Interest expense
4.12
2.48
0.84
Pre-tax income
1.29
3.79
2.44
4.82
-19.6
-6.85
-0.76
1.39
-0.9
-0.78
Income tax
0.38
0.17
-9.06
0.9
0.15
0
0.03
-0.02
-0.03
-0.26
Income from continuing operations
1.67
3.62
11.5
3.93
-19.8
-6.85
-0.73
1.37
-0.92
-1.04
Net income
1.67
27
43.4
3.93
-19.8
-6.85
-0.73
1.37
-0.92
-1.04
EPS, basic
0.12
1.80
2.78
0.25
-1.32
-0.64
-0.07
0.13
-0.09
-0.10
EPS, diluted
0.11
1.56
2.39
0.24
-1.32
-0.64
-0.07
0.13
-0.09
-0.10
Balance sheet
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Cash and equivalents
3.57
12.3
5.26
24.1
13
2.72
3.69
4.86
6.37
7.19
Receivables
17.2
8.59
10.8
10.2
5.25
4.66
5.64
4.79
5.3
Inventory
12.2
3.08
4.24
6.33
5.14
3.33
3.22
2.9
3.28
Total current assets
55.2
115
89.6
31.4
15.7
12.6
14.8
15.2
15.9
Property, plant and equipment
10.3
0.22
0.32
1.28
1.64
1.61
1.19
0.74
0.96
Goodwill
47.5
0
2.99
2.97
3.18
3.1
3.38
Intangible assets
101
1.76
1.71
9.6
13.6
11.2
10.6
8.94
9.35
Total assets
215
129
104
42.3
34.1
28.4
29.9
28.1
29.7
Accounts payable
17.9
10.4
14.4
9.38
6.98
6.67
7.13
7.6
7.93
Short-term debt
1.38
Total current liabilities
61.6
43.7
16.9
11.7
12.3
8.51
8.39
7.93
8.4
Lease liabilities
0.85
1.08
0.79
0.5
0.23
0.51
Total liabilities
176
48.2
20.2
15.3
14.9
10
8.89
8.16
8.9
Total debt
71.1
0
Paid-in capital
6.76
6.9
7.63
8.03
10.3
10.4
10.5
10.7
10.9
Retained earnings
-98
-54.5
-50.1
-62.6
-65.6
-66.3
-64.9
-65.9
-66.9
Shareholders' equity
36.2
80.7
Minority interests
2.09
Total equity
4.46
38.3
80.7
83.6
26.9
19.1
18.4
21
19.9
20.8
Total liabilities and equity
215
129
104
42.3
34.1
28.4
29.9
28.1
29.7
Cash flow statement
FY2015
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Net income
1.67
27
43.4
3.93
-19.8
-6.85
-0.73
1.37
-0.92
-1.04
Cash from operations
0.14
6.41
21.9
0.74
-14.6
-2.24
3.99
1.83
2.08
1.38
Cash from investing
-0.23
-42.2
54.2
19.7
34.3
-7.24
-2.69
-0.31
-0.27
-0.74
Debt issued
0.33
0.16
Debt repaid
62.6
Share buybacks
-3.02
-4.15
-0.52
0
Cash from financing
3.12
44.5
-83
-2.66
-30.3
-0.77
-0.32
-0.36
-0.3
-0.37
Exchange rate effect
1.14
-0.55
-0
-0
0
0
0.55
Net change in cash
3.07
8.7
-7.01
18.9
-11.2
-10.2
0.98
1.16
1.51
0.82
Interest paid
0.31
1.22
7.49
Income taxes paid
0.89
2.04
0.48
0.31
0
0.09
0.06
0.18
Key metrics
Worked out from the statements above. Latest values use fiscal 2024. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Gross margin
59.7%
Gross profit / revenue.
Pre-tax margin
-3.6%
Pre-tax income / revenue.
Net margin
-4.7%
Net income / revenue.
Operating cash flow margin
6.3%
Cash from operations / revenue.
Return on assets (ROA)
-3.6%
Net income / average total assets.
R&D / revenue
14.1%
Research and development expense / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
1.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
0.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
1.7%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-6.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
1.0%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
0.3%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y
-33.8%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y
-29.9%
Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
5.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
1.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-6.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.89x
Current assets / current liabilities.
Quick ratio
1.49x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.86x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
30.0%
Total liabilities / total assets.
Working capital
CA$7.5M
Current assets - current liabilities.
Goodwill and intangibles / assets
42.9%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.76x
Revenue / average total assets.
Fixed asset turnover
25.9x
Revenue / average property, plant and equipment.
Inventory turnover
2.85x
Cost of revenue / average inventory.
Days inventory
128 days
365 x average inventory / cost of revenue.
Receivables turnover
4.34x
Revenue / average receivables.
Days sales outstanding
84 days
365 x average receivables / revenue.
Days payables
322 days
365 x average accounts payable / cost of revenue.
Cash conversion cycle
-109 days
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-CA$0.10
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-CA$0.10
Net income per basic share, as reported (split-adjusted).
What was MEDICURE INC's revenue in fiscal 2024?
MEDICURE INC reported revenue of CA$21.9M for fiscal 2024, 1% higher than the year before.
Was MEDICURE INC profitable in fiscal 2024?
No. It reported a net loss of CA$1.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.